PMID- 11642337
OWN - NLM
STAT- MEDLINE
DCOM- 20020319
LR  - 20190719
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 24
IP  - 10
DP  - 2001 Oct
TI  - Synergistic effect of indomethacin with adriamycin and cisplatin on tumor growth.
PG  - 1214-7
AB  - In this study, we have examined the antitumor effect of combined administrations 
      of indomethacin (IND) with chemotherapeutic drugs on tumor growth. Colon 26 clone 
      20 (C20) cells and monocyte chemotactant protein-1 (MCP-1) transfected C20 cells 
      (C20betaA-2-1) were used and these cells were inoculated into the footpad of 
      BALB/c mice. At day 1 after tumor inoculation, treatment with 0.001% IND via the 
      drinking water was commenced. At days 4, 6, and 8, adriamycin or cisplatin was 
      administered intravenously at a dose of 5 mg/kg or intraperitoneally at a dose of 
      2 mg/kg, respectively. Although IND, adriamycin and cisplatin only partially 
      reduced the growth of the C20 tumors after treatment with each drug on its own, a 
      marked synergistic effect was observed when they were given in combination. A 
      synergistic effect between IND and cisplatin on C20betaA-2-1 was also observed. 
      However, IND itself showed no suppression of C20betaA-2-1 tumor growth. These 
      results suggest that combination of indomethacin with chemotherapeutic drugs 
      could be an effective form of cancer chemotherapy. The observed effects may be 
      dependent on the expression of MCP-1.
FAU - Hattori, K
AU  - Hattori K
AD  - Department of Fundamental Experimental Pharmaco-Science, Kyoritsu College of 
      Pharmacy, Tokyo, Japan.
FAU - Matsushita, R
AU  - Matsushita R
FAU - Kimura, K
AU  - Kimura K
FAU - Abe, Y
AU  - Abe Y
FAU - Nakashima, E
AU  - Nakashima E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Chemokine CCL2)
RN  - 80168379AG (Doxorubicin)
RN  - Q20Q21Q62J (Cisplatin)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*pharmacology
MH  - Antibiotics, Antineoplastic/*pharmacology
MH  - Antineoplastic Agents/*pharmacology
MH  - Cells, Cultured
MH  - Chemokine CCL2/biosynthesis/physiology
MH  - Cisplatin/*pharmacology
MH  - Colonic Neoplasms/*drug therapy/pathology
MH  - Doxorubicin/*pharmacology
MH  - Drug Synergism
MH  - Female
MH  - Humans
MH  - Immunotherapy
MH  - Indomethacin/*pharmacology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neoplasm Transplantation
MH  - Tumor Cells, Cultured
EDAT- 2001/10/20 10:00
MHDA- 2002/03/20 10:01
CRDT- 2001/10/20 10:00
PHST- 2001/10/20 10:00 [pubmed]
PHST- 2002/03/20 10:01 [medline]
PHST- 2001/10/20 10:00 [entrez]
AID - 10.1248/bpb.24.1214 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2001 Oct;24(10):1214-7. doi: 10.1248/bpb.24.1214.